Natco Pharma’s board of directors has approved a rights issue that will raise up to ₹1,279.36 crore by issuing 1.71 crore rights equity shares on a private placement basis. The issue will open on Monday, 12 October 2026 and close on Thursday, 22 October 2026, with an on‑market renunciation window from 12 to 16 October 2026. The rights issue price is ₹750 per share, a premium of ₹748 over the ₹2 face value. The record date for eligibility is Thursday, 1 October 2026.

On Friday, 25 September 2026, Natco Pharma shares traded in the red zone despite the board’s approval of the rights issue. The scrip reached an intraday high of ₹850.10 per unit before slipping into the red. At approximately 12:20 PM, the share price was ₹841.35, down 0.08 %. Over the past week the stock had risen more than 3 %, but it had fallen 3 % over the month and 5 % year‑to‑date. The 52‑week high was ₹1,226.80 on 12 May 2026, while the year’s low was ₹789 on 30 September 2025.

The board approved issuing 1.71 crore rights equity shares, each with a face value of ₹2. The rights will be offered to eligible shareholders at a ratio of two rights equity shares for every 21 fully paid‑up equity shares held on the record date. Shareholders holding fewer than 21 shares will receive no rights entitlement. If an eligible shareholder’s holding is not a multiple of 21, the fractional entitlement will be ignored, but such shareholders may apply for an additional rights equity share, subject to availability, and will receive preferential consideration for allotment. These additional shares cannot be renounced in favour of third parties, and the application forms are non‑negotiable.

The record date for determining eligibility is Thursday, 1 October 2026. The rights issue will open on Monday, 12 October 2026 and close on Thursday, 22 October 2026. An on‑market renunciation period is scheduled from Monday, 12 October to Friday, 16 October 2026. The board has fixed these dates to ensure a smooth subscription process for shareholders. Investors will need to hold the required number of shares on the record date to qualify for the rights allocation. The renunciation window allows shareholders to surrender their rights in exchange for cash or other securities, subject to the terms set by the board.

On 25 September 2026, Natco Pharma’s market capitalisation stood at ₹15,061.35 crore according to NSE data. The share price had slipped into the red zone after a brief rise to ₹850.10, falling to ₹841.35 at 12:20 PM. Over the preceding week the stock had gained more than 3 %, but it had declined 3 % over the month and 5 % year‑to‑date. The 52‑week high of ₹1,226.80 was recorded on 12 May 2026, while the year’s low of ₹789 occurred on 30 September 2025.